Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 14/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 3/20 | 0.38 |
| ▸ | CX3CR1 | P49238 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4997273 | 0.79 | DRD2 (0.49) | JAK2CYP2D6 | |
| SCHEMBL1074099 | 0.76 | JAK2 (0.47) | JAK2 | |
| SCHEMBL1019624 | 0.76 | DRD3 (0.45) | CXCR3JAK2 | |
| SCHEMBL4997917 | 0.75 | JAK2 (0.46) | JAK2 | |
| SCHEMBL1022272 | 0.75 | JAK2 (0.41) | CXCR3JAK2CYP2D6 | |
| SCHEMBL5005077 | 0.75 | MAP4K4 (0.43) | JAK2CYP2D6 | |
| SCHEMBL5001584 | 0.74 | JAK2 (0.41) | CXCR3JAK2CYP2D6 | |
| SCHEMBL1021257 | 0.74 | SCN1A (0.44) | CXCR3JAK2 | |
| SCHEMBL1020864 | 0.73 | OPRM1 (0.44) | JAK2 | |
| SCHEMBL1023234 | 0.73 | KDM4E (0.46) | CXCR3JAK2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751860-B2 | Piperidin-4YL-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-05 | — | — | US | disclosed |
| US-20170022181-A1 | FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | DE BRUYN MARCEL FRANS LEOPOLD (BE) | 2017-01-26 | — | — | US | disclosed |
| US-9468640-B2 | Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2016-10-18 | — | — | US | disclosed |
| US-20150141432-A1 | PIPERIDIN-4-YL-PYRIDAZIN-3-YLAMINE DERIVATIVES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-21 | — | — | US | disclosed |
| US-8940743-B2 | Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-27 | — | — | US | disclosed |
| EP-1943242-B1 | PIPERIDIN-4-YL-PYRIDAZIN-3-YLAMINE DERIVATIVES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-12 | — | — | EP | disclosed |
| US-20080227791-A1 | treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect without motor side effects; N-[1-(4-fluorobenzyl)piperidin-4-yl]-6-(trifluoromethyl)pyridazin-3-amine | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-18 | — | — | US | disclosed |
| EP-1943242-A1 | PIPERIDIN-4-YL-PYRIDAZIN-3-YLAMINE DERIVATIVES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007048779-A1 | PIPERIDIN-4-YL-PYRIDAZIN-3-YLAMINE DERIVATIVES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022181-A1 | FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | DRD2, GRIN2A, GRIN2C | CXCR3 4124/4885JAK2 2291/4885CCR1 4160/4885 |
| US-20080227791-A1 | treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect without motor side effects; N-[1-(4-fluorobenzyl)piperidin-4-yl]-6-(trifluoromethyl)pyridazin-3-amine | GRIN2C, GRIN2A, GRIN3A | CXCR3 4534/4885JAK2 1834/4885CCR1 3595/4885 |
| US-20150141432-A1 | PIPERIDIN-4-YL-PYRIDAZIN-3-YLAMINE DERIVATIVES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | DRD2, GRIN2C, GRIN2A | CXCR3 4579/4885JAK2 1290/4885CCR1 4250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.